Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth prospects and innovation
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
